Clinical Trial Update: Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela ) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating idelalisib in combination with bendamustine and rituximab for previously treated chronic lymphocytic leukemia has completed with resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Bendamustine (Bendamustine)
• Idelalisib (idelalisib)
• Rituximab (rituximab)

Snippet

Sponsor: Gilead Sciences | Conditions: Chronic Lymphocytic Leukemia | Phase 3 | Status: COMPLETED | Results posted: 2018-02-27